Smith And Nephew Plc (SNN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Smith and Nephew Plc  (NYSE: SNN)


Smith And Nephew Plc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Smith And Nephew Plc's ROI in the fourth quarter of 2025?
Smith and Nephew Plc achieved a return on average invested assets (ROI) of 7.29 % in its fourth quarter of 2025, which is below Smith And Nephew Plc's average return on investment, which stands at 9.8%.

ROI has improved compared to 4.65% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 161 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 1305.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -2.89 % 3.58 % 26.95 % 64.05 % 131.99 %
Y / Y Net Income Change TTM 51.7 % 56.65 % 56.65 % 56.65 % 56.65 %
Investment (TTM) in Millions 7,685 8,862 8,862 8,862 8,823
Return On Investment (TTM) 7.29 % 4.65 % 4.66 % 4.66 % 4.67 %
SNN's Overall Ranking # 1305 # 0 # # #
Seq. Investment Change TTM -3.21 % 0.11 % 0.11 % 0.11 % 3.24 %
Seq. Net Income Change TTM 51.7 % 0 % 0 % 0 % 56.65 %
Net Income (TTM) in Millions 625 412 412 412 412

SNN Company Profile >> Back to SNN Roi Comparisons >> See Annual SNN Return On Investment



Return On Investment SNN's Ranking
Within: No.
Industry # 48
Sector # 162
Overall # 1305

Return On Investment Statistics
High Average Low
11.58 %
9.8 %
7.29 %
(Dec 31 2024)   (Dec 31 2025)







Financial Statements
Smith And Nephew Plc's IV. Quarter Investments $ 7,685 Millions SNN's Balance sheet
Smith And Nephew Plc's IV. Quarter Income $ 625 Millions Quarterly SNN's Income Statement
SNN's Income by Division See SNN's Income by Division


SNN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 8,862 8,823 7,716 5,379 5,747
Y / Y Investment Growth 0.44 % 14.35 % 43.45 % -6.4 % 0.58 %
Net Income in Millions 625 412 263 223 524
Y / Y Net Income Growth 51.7 % 56.65 % 17.94 % -57.44 % 16.96 %
Annual Return On Investment 7.05 % 4.67 % 3.41 % 4.15 % 9.12 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 7.05 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SNN's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SNN's Competitors
Subscribers only: Roi for Smith And Nephew Plc's Suppliers
Subscribers only: Return On Investment for SNN's Customers

Other Ratios
SNN's Roa SNN's Inventory Turnover Ratio SNN's Growth Rates SNN's Dividend Statistics
SNN's Profitability Ratios SNN's Asset Turnover Ratio SNN's Dividend Growth
SNN's Roe SNN's Valuation Ratios SNN's Financial Strength Ratios SNN's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Astrazeneca Plc  19.67 %
Vertex Pharmaceuticals Inc  19.48 %
Inspire Medical Systems inc   19.34 %
Mimedx Group Inc   19.27 %
Gilead Sciences Inc   19.26 %
United Therapeutics Corporation  18.71 %
Krystal Biotech Inc   18.51 %
Agilent Technologies inc   18.50 %
Chemed Corporation  18.05 %
Hca Healthcare Inc   17.95 %
Sbc Medical Group Holdings Incorporated  17.85 %
Lifevantage Corp  17.77 %
Embecta Corp   17.69 %
Waters Corporation  17.39 %
Spero Therapeutics Inc   16.92 %
Johnson and Johnson  16.85 %
Halozyme Therapeutics Inc   16.47 %
Intuitive Surgical Inc   15.81 %
Black Diamond Therapeutics Inc   15.47 %
Strata Critical Medical Inc   15.07 %
Aveanna Healthcare Holdings Inc   14.96 %
Ironwood Pharmaceuticals inc   14.88 %
Argenx Se  14.81 %
Corcept Therapeutics Inc  14.64 %
Harmony Biosciences Holdings inc   14.44 %
Keros Therapeutics Inc   13.88 %
Sab Biotherapeutics Inc   13.87 %
West Pharmaceutical Services Inc   13.68 %
Inmode Ltd   13.49 %
Neurocrine Biosciences Inc   13.45 %

Date modified: 2026-09-08T15:11:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.